Vytorin in the Treatment of Alopecia Areata

Completed · Phase 1

Conditions studied: Alopecia Areata

In brief

Subjects, non pregnant/lactating and over 18years old, with 40% alopecia areata will take vytorin (statin/ezetimibe) for 24 or 52 weeks and be monitored for hair regrowth. The investigators hypothesize that Vytorin medication may have an effect on the inflammatory process of alopecia areata. Inactivating the inflammatory process may help in permitting hair regrowth in those subjects.

Key facts

Study ID: NCT01520077
Run by: University of Miami
People needed: 29
Starts: 2011-07-01
Expected to finish: 2015-01-01
Last updated by the study team: 2015-03-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

40-80% hair loss.
Clinical diagnosis of alopecia areata
18-years or older

You may not qualify if…

You are less than 18 years old
You are pregnant or planning to be pregnant during the next 12 months.
You are nursing a child.
You have kidney, liver or muscle disease.
You have an allergy to Lidocaine, the study drug or its components.
You are presently participating in another clinical trial
You are currently using, or have used within the past 3 months, the following:
Systemic corticosteroids. (prednisone, methylprednisolone, hydrocortisone etc.)
Immunosuppressant agents.(cyclosporine, efalizumab etc.)
Any medication that may have interaction with Vytorin (check with the study doctor for other medications you are taking).
You are currently using, or have used within the past 2 weeks, any topical medication for the treatment of alopecia areata
You have an ongoing hypothyroid problem that is not being treated. If this problem is being treated then you can participate.

Where it is running

University of Miami — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.